Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
25.72
+0.61 (2.43%)
May 1, 2024, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Employees
Mirum Pharmaceuticals had 264 employees on December 31, 2023. The number of employees increased by 68 or 34.69% compared to the previous year.
Employees
264
Change (1Y)
68
Growth (1Y)
34.69%
Revenue / Employee
$705,962
Profits / Employee
-$618,996
Market Cap
1.21B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 264 | 68 | 34.69% |
Dec 31, 2022 | 196 | 59 | 43.07% |
Dec 31, 2021 | 137 | 69 | 101.47% |
Dec 31, 2020 | 68 | 35 | 106.06% |
Dec 31, 2019 | 33 | 9 | 37.50% |
Dec 31, 2018 | 24 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Phreesia | 1,438 |
AtriCure | 1,050 |
Maravai LifeSciences Holdings | 650 |
Vir Biotechnology | 587 |
AbCellera Biologics | 586 |
Collegium Pharmaceutical | 197 |
Prothena Corporation | 173 |
Scholar Rock Holding | 150 |
MIRM News
- 12 hours ago - Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 - Business Wire
- 21 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome - Business Wire
- 7 weeks ago - US FDA approves expanded use of Mirum's liver disease drug - Reuters
- 7 weeks ago - Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis - Business Wire
- 2 months ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 - Business Wire